Previous Article | Next Article ![]()
Infection and Immunity, December 2002, p. 6805-6810, Vol. 70, No. 12
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.12.6805-6810.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Cellular Microbiology Research Group, Eastman Dental Institute for Oral Health Care Sciences, University College London, London WC1X 8LD, United Kingdom
Received 5 June 2002/ Returned for modification 12 July 2002/ Accepted 23 August 2002
|
|
|---|
|
|
|---|
Since foreign bodies become rapidly coated with plasma proteins when they are implanted in the body, S. epidermidis may bind to implants through interactions with immobilized extracellular matrix proteins. In vitro studies have shown that S. epidermidis can bind to biomaterials coated with fibronectin and fibrinogen (3, 5,9, 17). The ability of Staphylococcus aureus to bind to extracellular matrix proteins through a family of proteins termed the microbial surface components recognizing adhesive matrix molecules is well documented (for a review see reference 4). However, comparatively little is known about how S. epidermidis interacts with matrix proteins. It has been established that S. epidermidis binds to fibrinogen through SdrG, a microbial surface component recognizing adhesive matrix molecules, which is also known as Fbe (7, 16, 18, 19). The autolysin AtlE of S. epidermidis, which has been implicated as the mediator of primary attachment of this organism to polystyrene surfaces, has also been shown to bind vitronectin (8). Although it has been demonstrated that S. epidermidis binds to fibronectin in vitro (3, 5, 9), no fibronectin-binding protein has been identified yet. In fact, it has been suggested that teichoic acid may mediate binding of S. epidermidis to immobilized fibronectin (10). The aim of the work described in this paper was to use shotgun phage display cloning to identify S. epidermidis genes that code for fibronectin-binding proteins.
|
|
|---|
5 thi
(lac-proAB) F'(traD36 proAB+ lacIq lacZ
M15)] were used in the construction of the phage display library. E. coli was grown in nutrient broth no. 2 (Oxoid Ltd.). The medium was supplemented when appropriate with 100 µg of ampicillin per ml to maintain the phagemid. All cultures were grown at 37°C under aerobic conditions. Construction of the S. epidermidis phage display library. To construct the phage display library, S. epidermidis chromosomal DNA was sheared by sonication to obtain fragments between 0.5 and 2 kb long. Without further size fractionation, the chromosomal fragments were blunt ended by using the Klenow fragment and T4 DNA polymerase and then ligated to SnaBI-digested and dephosphorylated phagemid vector pG8SAET by using a Ready-to-Go T4 DNA ligase kit (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom). The ligated DNA was purified by using a QIAquick PCR purification kit (Qiagen Ltd., Crawley, United Kingdom) and was introduced by electroporation into E. coli TG1. The electroporated cells were allowed to recover for 2 h at 37°C in 10 ml of nutrient broth no. 2 prior to infection with helper phage R408 (Promega, Southampton, United Kingdom) at a multiplicity of infection of 20. The infected cells were grown overnight in 190 ml of nutrient broth no. 2 containing antibiotic. The phage were recovered from the culture supernatant by precipitation with a solution containing 20% (wt/vol) polyethylene glycol 8000 (Sigma-Aldrich Co. Ltd., Poole, United Kingdom) and 1 M NaCl, resuspended in phosphate-buffered saline (PBS) containing calcium and magnesium (PBSCM) (Sigma-Aldrich Co. Ltd.), and sterilized by passage through a 0.45-µm-pore-size filter.
Panning of the S. epidermidis phage library against fibronectin. A 5-ml Nunc Maxisorb immunotube (Invitrogen Ltd., Paisley, United Kingdom) was coated overnight at 4°C with 1 ml of a solution containing 1 mg of fibronectin from human plasma (Sigma-Aldrich Co. Ltd.). The tube was blocked with 4 ml of 2% bovine serum albumin (BSA) in PBSCM for 2 h at room temperature. After the tube had been extensively washed with PBSCM containing 0.05% Tween 20 and then with PBSCM, 1 ml of the S. epidermidis phage library was added to the tube and incubated for 2 h at room temperature. All unbound phage were removed by 10 washes with 4 ml of PBSCM containing 0.05% Tween 20, followed by 10 washes with 4 ml of PBSCM. The bound phage were eluted in 1 ml of 0.1 M glycine buffer (pH 2.1) for 10 min at room temperature, which was then neutralized with 0.5 ml of 1 M Tris-HCl buffer (pH 8.0).
Preparation of phage stocks. Stocks of phages pSE104FN and pSE109FN were prepared by infecting 2 ml of mid-exponential-phase E. coli TG1 containing the recombinant phagemids with the helper phage R408 at a multiplicity of infection of 20. After 30 min of incubation at 37°C, the infected cells were added to 190 ml of nutrient broth no. 2 containing ampicillin and grown overnight at 37°C. The phage particles were recovered from the culture supernatant by precipitation with 20% polyethylene glycol 8000-1 M NaCl, resuspended in PBSCM, and filter sterilized as described above.
Binding activity of recombinant phage.
Wells of Nunc Maxisorp microtiter plates (Invitrogen Ltd.) were coated overnight at 4°C with 0.1-ml aliquots of 0.1-mg/ml solutions of the following test ligands dissolved in PBS: fibronectin, the 30-kDa N-terminal and 45-kDa
-chymotryptic fragments of fibronectin, collagen (type I, acid soluble, from human placenta), fibrinogen (fraction I from human plasma), heparin, hyaluronate, mucin (from bovine submaxillary glands), plasminogen, and vitronectin, all of which were purchased from Sigma-Aldrich Co. Ltd.; mouse laminin (Collaborative Biomedical Products, Bedford, Mass.); and the 120-kDa
-chymotryptic fragment of fibronectin (Invitrogen Ltd.). The wells were each blocked with 0.1 ml of either 1% BSA or 1% Tween 20 in PBS for 1 h. After the wells were rinsed three times with PBS containing 0.05% Tween 20 and then with PBS, 0.1 ml of a 1 x 109-CFU/ml phage solution was added to each well and incubated for 1.5 h. The unbound phage was removed by five washes with 0.2 ml of PBS containing 0.05% Tween 20, followed by five washes with 0.2 ml of PBS. The bound phage were eluted with 0.1 ml of 0.1 M glycine buffer (pH 2.1) for 10 min and neutralized with 50 µl of 1 M Tris-HCl buffer (pH 8.0).
For inhibition studies with Embp32, microtiter plates were coated with fibronectin. After blocking and washing, 0.1 ml of one of a range of concentrations of the recombinant protein was added to each well, and the plates were incubated for 1 h before the phage solution was added as described above.
Titration of phage stocks. The number of phage were determined as CFU infecting E. coli TG1 grown to the mid-exponential phase with the phage solution. After 60 min of incubation at 37°C, the cells were plated onto nutrient broth no. 2 containing ampicillin.
Western blotting. Extracellular matrix components and plasma proteins were Western blotted to determine if there was any fibronectin contamination. Ligands (10 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 8% polyacrylamide gels and electroblotted onto Immobilon-P nitrocellulose membranes (Sigma-Aldrich Co. Ltd.). The membranes were blocked by incubating them with 5% milk in PBS containing 0.1% Triton X-100 for 1 h, after which they were incubated for 2 h with a 1:1,000 dilution of anti-human fibronectin mouse monoclonal antibody (Sigma-Aldrich Co. Ltd.). The membranes were washed five times with PBS containing 0.1% Triton X-100 and then incubated with goat anti-mouse immunoglobulin G (whole molecule; Sigma-Aldrich Co. Ltd.) at a 1:2,000 dilution. The membranes were washed as described above and developed with Sigma Fast DAB tablets (Sigma-Aldrich Co. Ltd.).
Inhibition of staphylococcal binding to fibronectin by Embp32 and FnBPB[D1-D4]. Wells of Nunc Maxisorp microtiter plates (Invitrogen Ltd.) were each coated overnight at 4°C with 0.2 ml of a 0.1-mg/ml solution of fibronectin. The wells were blocked with 0.2 ml of 1% Tween 20 in PBS for 1 h. After the wells were rinsed four times with PBS, 0.1-ml aliquots of different concentrations of Embp32 or FnBPB[D1-D4] (prepared as described by Nair et al. [S. P. Nair, H. Khalil, R. J. Williams, S. Ahmed, B. Henderson, and S. Meghji, submitted for publication]) were added to the wells and incubated for 1 h. Then 0.1 ml of either S. epidermidis NCTC11047 or S. aureus 8325-4 (corresponding to 5 x 107 cells) was added in triplicate to the appropriate wells and incubated for 1 h at 37°C. The wells were washed four times with 0.1 ml of PBS. The bound bacteria were harvested by addition of 0.1 ml of 0.25% trypsin to each well and incubation for 5 min at 37°C. The bound bacteria were counted by serial dilution and plate counting on blood agar base no. 2 plates containing 5% horse serum (Oxoid Ltd.).
Cloning of embp32. The oligonucleotides 5'-GGATCCCTACAACAAGCAAGTGCAACA-3' and 5'-CTGCAGTAGAAGTGCTCTAGCATCATC-3' were designed to amplify a 870-bp fragment of DNA encoding the putative fibronectin-binding region of Embp (Fig. 1) and contained recognition sequences (underlined) for the restriction enzymes BamHI and PstI, respectively. The PCR fragment was initially cloned into pCR4-TOPO (Invitrogen Ltd.) and transformed into E. coli TOP10. The insert was extracted from pCR4-TOPO on a BamHI-PstI fragment and ligated to BamHI- and PstI-digested pQE30 (Qiagen Ltd.). The ligation mixture was transformed into E. coli M607(pREP4) (Nair et al., submitted), and transformants were selected by growth at 30°C on Luria-Bertani agar containing 100 µg of ampicillin per ml, 25 µg of kanamycin per ml, 20 µg of spectinomycin per ml, and 20 µg of streptomycin per ml.
![]() View larger version (13K): [in a new window] |
FIG. 1. Alignment of the S. epidermidis DNA inserts within the fibronectin-binding phage. The bar at the top indicates the scale of the overlapping sequences. The dashed lines indicate the 364-bp region present in all inserts. The numbers in parentheses are the numbers of clones analyzed that contained the inserts. The inserts in phages pSE104FN and pSE109FN are shown. The region coding for the recombinant protein (Embp32) used in the inhibition studies is also shown.
|
Reverse transcription (RT)-PCR analysis of embp expression. Overnight cultures of S. epidermidis NCTC11047 grown in brain heart infusion broth (Oxoid Ltd.) were diluted to an absorbance at 650 nm of 0.1 in fresh broth and incubated at 37°C with aeration. Aliquots containing 1 x 109 cells were removed at various times, and total cellular RNA was extracted by using an RNeasy mini kit (Qiagen Ltd.) according to the manufacturer's instructions, except that the cells were lysed with 100 µl of a 2.5-mg/ml lysostaphin solution and 20 µl of a 50-mg/ml lysozyme solution for 5 min at 37°C. The purified RNA was treated with RNase-free DNase (Promega), and cDNA was prepared from 2 µg of RNA by using random hexamers and Superscript II (Invitrogen Ltd.) according to the manufacturer's instructions. PCR screening for the embp gene was performed by using 1.5 µl of the cDNA and the oligonucleotides 5'-AGCGGTACAAATGTCAATATC-3' and 5'-AGAAGTGCTCTAGCATCATCC-3', which were designed to amplify a 455-bp region of embp.
DNA manipulations and sequencing. All DNA manipulations were carried out by using standard procedures (21). Phagemid DNA was extracted with a QIAprep spin miniprep kit (Qiagen Ltd.). The insert DNA was sequenced from the 5' and 3' ends with the oligonucleotides 5'-AGGTACATTACTTATATCTGG-3' and 5'-CCGCTTTTGCGGGATCGTCAC-3', respectively, by cycle sequencing performed with a BigDye terminator kit (ABI Perkin-Elmer, Warrington, United Kingdom). The sequencing reactions were performed with an ABI 310 genetic analyzer. Homology searches were carried out against sequence databases by using the BLAST algorithm with either the nucleotide sequence of the S. epidermidis insert DNA or the predicted amino acid sequence in frame with the open reading frame encoded by gene VIII of the phagemid. Preliminary sequence data for S. epidermidis was obtained from The Institute for Genomic Research (TIGR) website (http://www.tigr.org).
Nucleotide sequence accession number. The nucleotide sequence of embp32 from S. epidermidis strain NCTC11047 has been deposited in the GenBank database under accession number AY101364.
|
|
|---|
Capacity of recombinant phage to bind to fibronectin. Two of the phagemid clones, pSE104FN and pSE109FN, containing 661- and 1,378-bp inserts, respectively (Fig. 1), were used in studies to confirm that the recombinant phage had the capacity to bind to fibronectin. Phage stocks of pSE104FN and pSE109FN were panned against BSA and fibronectin immobilized on microtiter plate wells. A total of 4.6 x 105 pSE109FN phage particles (range, 4.32 x 105 to 4.86 x 105) were recovered from the fibronectin-coated wells, whereas no phage bound to BSA. Similar results were obtained with phage pSE104FN, suggesting that these phagemids contained S. epidermidis DNA inserts encoding a fibronectin-binding domain. To confirm that the binding capacity was specific, the ability of the recombinant protein Embp32 to inhibit binding of phage pSE109FN to fibronectin was examined. Embp32 contains the predicted fibronectin-binding domain of Embp and has the same N-terminal start point as the peptide displayed by phage pSE104FN (Fig. 1). Preincubation of fibronectin-coated wells with graded concentrations of Embp32 inhibited binding of pSE109FN to fibronectin in a dose-dependent manner (Fig. 2). While no inhibition was evident after preincubation with a 0.3 µM solution of Embp32, 1.5 and 3 µM solutions inhibited binding by 61 and 84%, respectively. These results demonstrated that there was a specific interaction between the recombinant phage and fibronectin and that the phage expressed a fibronectin-binding domain.
![]() View larger version (13K): [in a new window] |
FIG. 2. Binding of phage pSE109FN to fibronectin preincubated with graded concentrations of Embp32. A binding value of 100% corresponded to the binding measured in wells preincubated with PBS. The results of one representative experiment of at least three experiments are shown. The data are the means and standard deviations for triplicate wells. An asterisk indicates that the P value is <0.05.
|
-chymotryptic fragment, and there was negligible binding to both the 30- and 120-kDa fragments compared to the binding to whole fibronectin (Table 1). |
View this table: [in a new window] |
TABLE 1. Numbers of recombinant phage binding to fibronectin and proteolytic fragments of fibronectin
|
|
View this table: [in a new window] |
TABLE 2. Numbers of recombinant phage particles that bound to the immobilized ligands
|
![]() View larger version (14K): [in a new window] |
FIG. 3. Binding of S. epidermidis to fibronectin preincubated with graded concentrations of Embp32. A binding value of 100% corresponded to the binding measured in wells preincubated with PBS. The results of one representative experiment of at least three experiments are shown. The data are the means and standard deviations for triplicate counts from triplicate wells. One asterisk indicates that the P value is <0.05, and three asterisks indicate that the P value is <0.005.
|
![]() View larger version (13K): [in a new window] |
FIG. 4. Effect of preincubating fibronectin-coated wells with either recombinant Embp32 or FnBPB[D1-D4] on the binding of staphylococci to fibronectin. (A) Binding of S. epidermidis to fibronectin preincubated with 13 µM Embp32 or FnBPB[D1-D4]. (B) Binding of S. aureus to fibronectin preincubated with 13 µM Embp32 or FnBPB[D1-D4]. A binding value of 100% corresponded to the binding measured in wells preincubated with PBS. The results of one representative experiment of at least three experiments are shown. The data are the means and standard deviations for triplicate counts from triplicate wells. Three asterisks indicate that the P value is <0.005.
|
![]() View larger version (26K): [in a new window] |
FIG. 5. Expression of the embp gene in S. epidermidis NCTC11047. A 455-bp embp product was PCR amplified from cDNA prepared from total RNA extracted at each of the times shown. OD650, optical density at 650 nm; C, S. epidermidis NCTC11047 genomic DNA used as a template in the PCR.
|
|
|
|---|
Confirmation that the recombinant phage displayed a fibronectin-binding domain from S. epidermidis was obtained by panning two of the phage, pSE104FN and pSE109FN, against microtiter plates coated with either BSA or fibronectin. Further confirmation of the specificity of binding was obtained by determining that a recombinant protein, Embp32, encompassing the predicted fibronectin-binding domain of Embp, blocked binding of pSE109FN to fibronectin.
The fibronectin-binding proteins of a number of bacteria, including S. aureus and Streptococcus pyogenes, have been shown to bind to a 30-kDa N-terminal region of fibronectin (12, 15). In this study we attempted to map the portion of fibronectin to which the phage encoding the fibronectin-binding domain of S. epidermidis bound. None of the proteolytic fragments of fibronectin tested, including the 30-kDa N-terminal fragment, bound to phage pSE109FN to an appreciable extent. This demonstrates that the S. epidermidis fibronectin-binding domain identified in this study interacts with fibronectin at a site distinct from the site utilized by the S. aureus and S. pyogenes fibronectin-binding proteins. At present it is unclear whether the interaction is with a fragment of fibronectin not examined in this study or whether the interaction site spans two of the fragments examined.
The ability of one of the phages displaying the S. epidermidis fibronectin-binding domain, pSE109FN, to bind to a number of other human matrix and plasma components was examined. No binding to the matrix proteins collagen, laminin, fibrinogen, and vitronectin was observed. Binding to plasminogen was detected, although the level of this binding was more than 100-fold less than that observed for fibronectin. Phage binding to two nonproteinaceous matrix components, heparin and hyaluronate, was also detected, but once again the levels of binding were more than 100-fold less than the level of binding observed with fibronectin. Western ligand blot analysis revealed that most of the matrix and plasma components tested were free of fibronectin contamination; the only exception was fibrinogen, which contained low levels of contaminating fibronectin. Thus, the interactions of pSE109FN with plasminogen, heparin, and hyaluronate were not due to fibronectin contamination. Interestingly it has been reported that heparin can inhibit binding of S. epidermidis to fibronectin-coated implants but not to fibrinogen-coated implants (5). Since the fibronectin-binding domain of S. epidermidis identified in this study binds to other matrix components, we have designated the protein extracellular matrix-binding protein (Embp).
We have also shown that the recombinant protein Embp32 blocks binding of S. epidermidis to fibronectin in a dose-dependent manner. The fact that the binding of S. epidermidis to fibronectin was blocked by 91% at the highest concentration of Embp32 examined suggests that either the Embp protein identified in this study is the major fibronectin-binding protein of S. epidermidis or that any other fibronectin-binding proteins possessed by this bacterium bind to the same region of fibronectin as Embp. Interestingly, the recombinant protein FnBPB[D1-D4], encompassing the D1-D4 repeat region of S. aureus FnBPB, has a negligible effect on the binding of S. epidermidis to fibronectin. Similarly, Embp32 does not inhibit the binding of S. aureus to fibronectin, whereas FnBPB[D1-D4] does. This can be explained by the finding that Embp, as determined by our phage-binding studies, binds to a region of fibronectin distinct from the 30-kDa N-terminal region to which the S. aureus fibronectin-binding proteins bind. These results demonstrate that S. aureus and S. epidermidis have discrete fibronectin-binding proteins that have distinct molecular interactions with fibronectin.
We thank L. Frykberg for the kind gift of phagemid pG8SAET. Preliminary sequence data were obtained from the TIGR website (http://www.tigr.org). Sequencing of the S. epidermidis genome was accomplished with support from NIH and NIAID.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»